珂立苏预防新生儿呼吸窘迫综合征的临床研究

Clinical values of calsurf on preventing neonatal respiratory distress syndrome

目的探讨珂立苏对预防新生儿呼吸窘迫综合征(NRDS)的有效性。方法将小于30周早产儿及30～32周高危早产儿55例分为实验组和对照组,实验组在出生后尽早经气管内滴入肺表面活性物质,对照组不使用。比较两组患儿的NRDS发生率、严重程度、FiO2、血气分析、吸氧方式及转归。结果实验组发生NRDS率为13.3%,对照组发生NRDS率为36.0%,两者相比,差异有统计学意义(P<0.05),且实验组患儿出现NRDS程度较对照组程度轻。实验组患儿治疗后6h血气分析显示PaO2明显高于对照组,差异有统计学意义(P<0.05),而PaCO2及FiO2明显低于对照组(P<0.05)。实验组吸氧方式及转归好于对照组,但差异无统计学意义(P>0.05)。结论珂立苏可以有效预防早产儿NRDS发生,减轻NRDS程度,改善氧合及通气,降低病死率,是一种安全有效的生物制剂。

Objective To explore the clinical values of calsurf on preventing neonatal respiratory distress syndrome in premature infants.Methods Fifty-five cases premature infants that were less than 30 weeks or with high risk factors between 30 to 32 weeks were selected as experimental group giving calsurf as quickly as possible.The dose of calsurf was 40～70mg/kg.Another 25 premature infants match these creteria but not using calsurf as control group.To compare the incidence of respiratory distress syndrome,the degrees of respiratory distress syndrome,FiO2,blood gas analysis,the ways of oxygen uptake and prognosis.Results The rate of NRDS was 13.3% in the experimental group,36.0% was in the control group.Differences between two groups were statistically significant（P0.05）.The levels of NRDS in experimental group were lighter than that in control group.Conclusion Calsurf is effective in preventing preterm infants NRDS,reducing the extents of NRDS improving oxygen close and ventilation,reducing mortality and complications.Calsurf is safe and effective in clinical use.